Biotech Values

[DewDiligence]

You’ve done an admiral job of tracking the AGI-1067 story. A few questions:

1. What is your probability that AZN stays in the program?

2. Assuming that there is no immediate FDA submission: a) What is your probability that the drug is repositioned as a diabetes treatment? b) What is your probability that the drug will ultimately be approved?

3. As a courtesy, can you break out the reported HR for each component—and each combination of components that was reported or can be calculated—of the primary efficacy endpoint?

4. What, if anything, did you learn from your discussion with MH?

T.i.a. Dew